JP2024536581A5 - - Google Patents
Info
- Publication number
- JP2024536581A5 JP2024536581A5 JP2024523674A JP2024523674A JP2024536581A5 JP 2024536581 A5 JP2024536581 A5 JP 2024536581A5 JP 2024523674 A JP2024523674 A JP 2024523674A JP 2024523674 A JP2024523674 A JP 2024523674A JP 2024536581 A5 JP2024536581 A5 JP 2024536581A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cbd
- subject
- asd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163271015P | 2021-10-22 | 2021-10-22 | |
| US63/271,015 | 2021-10-22 | ||
| PCT/US2022/078449 WO2023070045A1 (en) | 2021-10-22 | 2022-10-20 | Treatment of irritability in subjects with autism spectrum disorders with moderate to severe anxiety and/or social avoidance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024536581A JP2024536581A (ja) | 2024-10-04 |
| JP2024536581A5 true JP2024536581A5 (enExample) | 2025-10-27 |
Family
ID=84358575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523674A Pending JP2024536581A (ja) | 2021-10-22 | 2022-10-20 | 中等度から重度の不安及び／又は社会回避を伴う自閉症スペクトラム障害を有する対象における興奮性の治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240342198A1 (enExample) |
| EP (1) | EP4419091A1 (enExample) |
| JP (1) | JP2024536581A (enExample) |
| KR (1) | KR20240093852A (enExample) |
| CN (1) | CN118284412A (enExample) |
| AU (1) | AU2022373753A1 (enExample) |
| CA (1) | CA3235677A1 (enExample) |
| IL (1) | IL312328A (enExample) |
| MX (1) | MX2024004766A (enExample) |
| WO (1) | WO2023070045A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| CA3300266A1 (en) | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
| WO2010127033A1 (en) | 2009-04-28 | 2010-11-04 | Alltranz Inc. | Formulations of cannabidiol and methods of using the same |
| CA3300266A1 (en) * | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| WO2019224824A1 (en) * | 2018-05-24 | 2019-11-28 | To Pharmaceuticals Llc | Cannabis-based compositions for the treatment of autistic spectrum disorders |
| JP7856584B2 (ja) * | 2020-05-26 | 2026-05-11 | ハーモニー・バイオサイエンシズ・マネージメント・インコーポレイテッド | カンナビジオールを用いた自閉症スペクトラム障害の処置 |
| TWI902836B (zh) * | 2020-06-29 | 2025-11-01 | 美商和諧生物科學管理股份有限公司 | 以大麻二酚(cannabidiol)治療X染色體脆折症候群 |
| LT4243797T (lt) * | 2020-11-16 | 2026-06-10 | Orcosa Inc. | Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui |
-
2022
- 2022-10-20 CN CN202280077354.9A patent/CN118284412A/zh active Pending
- 2022-10-20 MX MX2024004766A patent/MX2024004766A/es unknown
- 2022-10-20 IL IL312328A patent/IL312328A/en unknown
- 2022-10-20 WO PCT/US2022/078449 patent/WO2023070045A1/en not_active Ceased
- 2022-10-20 KR KR1020247016925A patent/KR20240093852A/ko active Pending
- 2022-10-20 JP JP2024523674A patent/JP2024536581A/ja active Pending
- 2022-10-20 AU AU2022373753A patent/AU2022373753A1/en active Pending
- 2022-10-20 CA CA3235677A patent/CA3235677A1/en active Pending
- 2022-10-20 EP EP22803457.5A patent/EP4419091A1/en active Pending
-
2024
- 2024-04-22 US US18/642,059 patent/US20240342198A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10787502B2 (en) | Mast cell stabilizers for treatment of hypercytokinemia and viral infection | |
| EP2799071B1 (en) | Levocetirizine and montelukast for the treatment of influenza and common cold | |
| JP2025510295A5 (enExample) | ||
| WO2019224824A1 (en) | Cannabis-based compositions for the treatment of autistic spectrum disorders | |
| IL299399A (en) | Treatment of fragile X syndrome with cannabidiol | |
| Passàli et al. | Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study | |
| IL312328A (en) | Treatment of irritability in patients on the autism spectrum with moderate to severe anxiety and/or social avoidance | |
| JP2021517128A5 (enExample) | ||
| CN112618524A (zh) | 一种改善睡眠障碍的asbdv组合物及其制剂与应用 | |
| CN105496992A (zh) | 氨溴索沙丁胺醇脂质固体分散体 | |
| JP2013049729A (ja) | 医薬組成物 | |
| JP2006008540A (ja) | 風邪薬 | |
| JP4913359B2 (ja) | イブプロフェン含有医薬組成物 | |
| CN105496991A (zh) | 氨溴索沙丁胺醇口服液的制备方法 | |
| JP2004269517A (ja) | 医薬組成物 | |
| JPWO2005063253A1 (ja) | アレルギー症状治療用医薬組成物 | |
| HU et al. | Effects of tetramethylpyrazine on analgesia and neuronal damage in migraine rats by regulating SIRT1/AMPK/PGC1α signaling pathway | |
| Toholka et al. | Contact urticaria caused by preservatives and disinfectants | |
| WO2013030058A1 (de) | Verwendung von diclofenac | |
| RU2498797C2 (ru) | Комбинированное средство для лечения гриппа и орви | |
| CN121370891A (zh) | 麦角胺在制备治疗创伤后应激障碍的药物中的应用 | |
| CN105362226A (zh) | 氨溴索沙丁胺醇气雾剂的制备方法 | |
| CN105456240A (zh) | 氨溴索沙丁胺醇气雾剂 | |
| CN105434411A (zh) | 氨溴索沙丁胺醇口服液 | |
| EA049313B1 (ru) | Применение 2-(имидазол-4-ил)этанамид пентандиовой-1,5 кислоты для лечения covid-19 |